Mon, Dec 22, 2014, 3:17 AM EST - U.S. Markets open in 6 hrs 13 mins

Recent

% | $
Quotes you view appear here for quick access.

Alimera Sciences, Inc. (ALIM) Message Board

SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • According to Alimera, outside of Iluvien, they have something going with Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. This is the pipeline. Is there anyone who knows more about this?

    Sentiment: Buy

  • Got more than they thought with the FDA and much better than in Europe.$25KK Hercules loan with interest only payments until 2015. Will need more cash for US launch and will get either from debt refinancing and/or stock offer. UK up 25%, Germany flat, wait for November update. 1000 applications so far with NO IOP operations. Agnostic on M&A; but with global rights and sales force the business is attractive. Disappointed in market reaction but belief is because of the lack of liquidity and that new stock owners will enter to replace old owners ( my read is that now it is forming a base). Again there were only a few questions and very little analyst coverage led by Wells Fargo and 2 lesser known brokers.I expected Morgan Stanley to be on the call because they covered them 2 years ago; but nothing. I'm going to hold on until November and see what happens; It will rest for awhile with new owners that came in with the high volume after the news. 31,500 shares.

    Sentiment: Hold

  • I don't see anyone talking about ALIM having anything to offer in the future besides Iluvien. It looks like it's ILUVIEN or BUST. No pipeline means a dead end for Alimera. Everything, for now and forever, hinges on revenues from Iluvien. That's why a buyout should be considered. Sooner is better than later. Entice Big Pharm with potential revenues. Let them have all the marketing headaches and take all the risks. We shareholders will come out just fine. A buyout should bring us at least 12 - 15 dollars a share. We'd all be ahead.

    Sentiment: Buy

  • Reply to

    Bears in Control..

    by shaun7703 Oct 2, 2014 10:51 AM
    yi71@rocketmail.com yi71 Oct 2, 2014 1:07 PM Flag

    Management, or should I say "insiders" ( who control any decision regarding a buyout ) prefer to prove they can be successful on their own. They don't want to sell just as they finally have an opportunity to market a product that could make some money. They want to prove they are a success. I'm with you. I want a buyout. There is no investor confidence in ALIM despite the recent FDA approval. The stock could languish for a long time. I think the company is worth 2 - 3 times it's current market cap. That's a 10 - 15 dollar exit price for us. ALIM looks like a one trick pony. Is there anything of consequence in the pipeline? I don't think so. It's Iluvien or bust. ALIM has a big headache ahead hiring reps and marketing the drug. Things could go wrong for us shareholders. One bad treatment result could bring on a lawsuit. Why not let Big Pharma handle these headaches and take all the risks?. They have the know-how and the clout. Personal pride is getting in the way of a buyout deal right now..

    Sentiment: Buy

  • Reply to

    Bears in Control..

    by shaun7703 Oct 2, 2014 10:51 AM

    That would be nice .

    Sentiment: Strong Buy

  • Reply to

    Bears in Control..

    by shaun7703 Oct 2, 2014 10:51 AM

    Agreed or get 10-20 times its market cap from a buyout, 5bil my estimate. Figure a 10 yr time line and it will be up with the big boys.

    Sentiment: Strong Buy

  • Reply to

    Bears in Control..

    by shaun7703 Oct 2, 2014 10:51 AM

    Alimera Sciences, Inc. (ALIM) is holding its own on another down market.

    Sentiment: Buy

  • Reply to

    Bears in Control..

    by shaun7703 Oct 2, 2014 10:51 AM

    No just the short term traders who base their emotions on a tickers movement then they panic and sell when it doesn't go their way. Look at the fundamentals, this is a huge market that we are tapping into soon. By the time we get to the Q1 results it will be too late for most to get in at such cheap prices.

  • Bulls have given up on this?

  • If this stock drops more tomorrow I will average down my pps. Good opportunity cause this is only going up from here. Patience will pay off soon guys.

    Sentiment: Buy

  • Reply to

    Chances of buyout.

    by jacobv966 Oct 1, 2014 10:31 AM
    yi71@rocketmail.com yi71 Oct 1, 2014 10:08 PM Flag

    Despite the benefit I get, if any, from issuing my message barbs, I want to see Alimera succeed. I don't know or care much about the company per se, but as an investor (or captive shareholder) who will hold on to his shares, I want to see the hopes of all who have been faithful through the years come to fruition. I fully recognize and agree with your thoughts about a buyout being pretty slim at the moment. I hope all those who have confidence in success with Iluvien, and with Alimera's strategy and ability to execute going forward, are right.

    Sentiment: Buy

  • Reply to

    still manipulated

    by blnakhaet Oct 1, 2014 9:25 PM

    You are delusional, people will not sell which with the small float, it can only go up. Short interest has decreased drama over the past 3 days. Look for a good upswing because of the shorts and the stock is dirt cheap for a company with a FDA approval.

    Sentiment: Strong Buy

  • Reply to

    Chances of buyout.

    by jacobv966 Oct 1, 2014 10:31 AM

    You realize when and if this takes off, the company will be worth 10 times what it is now. So, the acquirer would have to come up with 6bil to get the company. As it stands right now there is no cure for diabetes and when it goes international the sky is the least, more people every year and growing. This is a three year cure for the people. No pricking, no checking blood sugar levels. The 5bil. buyout might be a little light. Amazing where the stock is with a long term cure. I'm done, no pumping, just telling the TRUTH!!!!!!!!

    Sentiment: Strong Buy

  • If I were to manipulate this stock, I'd keep it under 5 for a few days. Many people would get the margin call. Once they are gone, time to party. Watch it fall under 5 in a few days.

  • Reply to

    A race for revenues

    by yi71 Sep 30, 2014 4:25 PM

    They are not HIRING them, their parent company is. Also, the reason the stock did not go up is the company will not receive any revenue. until the end of 1st. qtr. of 2015.

    Sentiment: Hold

  • Reply to

    A race for revenues

    by yi71 Sep 30, 2014 4:25 PM

    Hey Bud, ALIM does not have any cost incurred on the sale of the diabetic procedure. They now get the 20% on every deal. I agree, the price should have doubled on the FDA approval. GL to all.

    Sentiment: Strong Buy

  • Reply to

    A race for revenues

    by yi71 Sep 30, 2014 4:25 PM

    Yi, Medidur is the very same drug as Iluvien. One difference however, is that pSivida will have Medidur in a 27 gauge needle. This was stated in the last PSDV CC by Paul Ashton.
    The time horizon for Medidur if approved looks to be 17' however, so Iluvien has two years of marketing without any conflict of crossover use. I wouldn't worry, ALIM looks to be pretty grounded now and retina docs should be very interested in the availability of Iluvien.

  • Reply to

    Where's shorty now?

    by doctorpsionic Sep 30, 2014 1:40 PM

    Shorty making bank!

  • Reply to

    Chances of buyout.

    by jacobv966 Oct 1, 2014 10:31 AM

    Thank you for the info. Wish I could have tuned in. They have been waiting for this day for years, since the first FDA app. Now they can execute. This stock is going to go up. There is just no way around it! And fyi, the market is down 250 points. No sense in losing sleep on a down day provided the long term chart show up

  • yi71@rocketmail.com yi71 Oct 1, 2014 1:56 PM Flag

    Getting insurance companies to pay is crucial.

    Sentiment: Buy

ALIM
5.84+0.11(+1.92%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.